News Archive

“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. This edition features 5 Questions Martha Schoonmaker, Executive Director, Pinkney Innovation Complex for Science and Technology at Montgomery College (PIC MC).

Martha Schoonmaker is the first Executive Director for the PIC MC Foundation, the entity that develops, manages, and markets the Germantown campus on behalf of Montgomery College for company locations. PIC MC is an integrated academic, business, and research campus and is the only community college with a hospital, Holy Cross Germantown Hospital, located as the anchor resident partner.

This event is free for biotech leaders is presented by BioHealth Innovation, VirginiaBio, Children’s National Health System, Deloitte, JLABS @ Washington D.C., Johns Hopkins University, Maryland Department of Commerce, Quality Biologics, George Mason University, University System of Maryland and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. Please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

 New Members Continue BHI’s Commitment and Mission in the BioHealth Capital Region

ROCKVILLE, MARYLAND, October 20, 2020 – The Board of Directors of BioHealth Innovation, Inc. (BHI) unanimously approved the appointments of three new board members, Sally Allain, Head of JLABS @ Washington, DC, Joseph F. Sanchez, PhD,  Director, Science Engagement, R&D North America, AstraZeneca, and Robert Silverman, Chief Business Officer, Alloy Therapeutics, Inc. BHI’s leadership also thanked outgoing Board of Director member Tracey Vetterick, formally of AstraZeneca for her contributions to the organization and support of many years.

The U.S. government is providing roughly $486 million to AstraZeneca to accelerate the Big Pharma company’s experimental Covid-19 therapy.

The funds will be used to advance AstraZeneca’s antibody combination, AZD7442, into two phase-III clinical trials. The last-stage studies, expected to begin later this month or early next month, will involve more than 6,000 study participants at sites in and outside the United States. (Phase-III clinical trials are typically the last hurdle a pharmaceutical company must successfully clear before seeking approval for a new drug candidate.)

Thank you for your interest in the 6th Annual BioHealth Capital Region Forum on Monday, October 19, 2020 that will highlight the accomplishments of today and chart our successes of tomorrow.

We are thrilled to welcome executive-level biohealth industry leaders from across the country and overseas. To make the best use of your time and enable you to network with our 1000+ registrants and learn from the 58+ industry speakers, please use the instructions below to join our virtual event platform, https://eventmobi.com/biohealth2020